Activity of ETX0462 toward Some Burkholderia spp

Burkholderia cepacia complex (Bcc) and Burkholderia gladioli are opportunistic human pathogens that are inherently multidrug resistant, limiting treatment options for infections. Here, a novel diazabicyclooctane, ETX0462, was evaluated for activity against Bcc and B . gladioli . Burkholderia cepacia...

Full description

Saved in:
Bibliographic Details
Published inAntimicrobial agents and chemotherapy Vol. 67; no. 1; p. e0135222
Main Authors Zeiser, Elise T., Becka, Scott A., LiPuma, John J., Papp-Wallace, Krisztina M.
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 24.01.2023
Subjects
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Antimicrobial Chemotherapy
Burkholderia
Burkholderia cepacia complex
Burkholderia Infections - drug therapy
Ceftazidime - therapeutic use
Humans
Susceptibility
Trimethoprim, Sulfamethoxazole Drug Combination - pharmacology
Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use
ETX0462
beta-lactamase
Burkholderia
penicillin binding protein
beta-lactam
diazabicyclooctane
Online AccessGet full text

Cover

Abstract Burkholderia cepacia complex (Bcc) and Burkholderia gladioli are opportunistic human pathogens that are inherently multidrug resistant, limiting treatment options for infections. Here, a novel diazabicyclooctane, ETX0462, was evaluated for activity against Bcc and B . gladioli . Burkholderia cepacia complex (Bcc) and Burkholderia gladioli are opportunistic human pathogens that are inherently multidrug resistant, limiting treatment options for infections. Here, a novel diazabicyclooctane, ETX0462, was evaluated for activity against Bcc and B . gladioli . Ninety-eight percent of the isolates examined in this study were susceptible. ETX0462 was found to demonstrate in vitro activity superior to that of currently available treatment options (e.g., trimethoprim-sulfamethoxazole and ceftazidime).
AbstractList Burkholderia cepacia complex (Bcc) and Burkholderia gladioli are opportunistic human pathogens that are inherently multidrug resistant, limiting treatment options for infections. Here, a novel diazabicyclooctane, ETX0462, was evaluated for activity against Bcc and . . Ninety-eight percent of the isolates examined in this study were susceptible. ETX0462 was found to demonstrate activity superior to that of currently available treatment options (e.g., trimethoprim-sulfamethoxazole and ceftazidime).
Burkholderia cepacia complex (Bcc) and Burkholderia gladioli are opportunistic human pathogens that are inherently multidrug resistant, limiting treatment options for infections. Here, a novel diazabicyclooctane, ETX0462, was evaluated for activity against Bcc and B. gladioli. Ninety-eight percent of the isolates examined in this study were susceptible. ETX0462 was found to demonstrate in vitro activity superior to that of currently available treatment options (e.g., trimethoprim-sulfamethoxazole and ceftazidime).Burkholderia cepacia complex (Bcc) and Burkholderia gladioli are opportunistic human pathogens that are inherently multidrug resistant, limiting treatment options for infections. Here, a novel diazabicyclooctane, ETX0462, was evaluated for activity against Bcc and B. gladioli. Ninety-eight percent of the isolates examined in this study were susceptible. ETX0462 was found to demonstrate in vitro activity superior to that of currently available treatment options (e.g., trimethoprim-sulfamethoxazole and ceftazidime).
Burkholderia cepacia complex (Bcc) and Burkholderia gladioli are opportunistic human pathogens that are inherently multidrug resistant, limiting treatment options for infections. Here, a novel diazabicyclooctane, ETX0462, was evaluated for activity against Bcc and B . gladioli . Burkholderia cepacia complex (Bcc) and Burkholderia gladioli are opportunistic human pathogens that are inherently multidrug resistant, limiting treatment options for infections. Here, a novel diazabicyclooctane, ETX0462, was evaluated for activity against Bcc and B . gladioli . Ninety-eight percent of the isolates examined in this study were susceptible. ETX0462 was found to demonstrate in vitro activity superior to that of currently available treatment options (e.g., trimethoprim-sulfamethoxazole and ceftazidime).
Burkholderia cepacia complex (Bcc) and Burkholderia gladioli are opportunistic human pathogens that are inherently multidrug resistant, limiting treatment options for infections. Here, a novel diazabicyclooctane, ETX0462, was evaluated for activity against Bcc and B . gladioli . Ninety-eight percent of the isolates examined in this study were susceptible. ETX0462 was found to demonstrate in vitro activity superior to that of currently available treatment options (e.g., trimethoprim-sulfamethoxazole and ceftazidime).
Burkholderia cepacia complex (Bcc) and Burkholderia gladioli are opportunistic human pathogens that are inherently multidrug resistant, limiting treatment options for infections. Here, a novel diazabicyclooctane, ETX0462, was evaluated for activity against Bcc and B. gladioli. Ninety-eight percent of the isolates examined in this study were susceptible. ETX0462 was found to demonstrate in vitro activity superior to that of currently available treatment options (e.g., trimethoprim-sulfamethoxazole and ceftazidime).
Author LiPuma, John J.
Papp-Wallace, Krisztina M.
Zeiser, Elise T.
Becka, Scott A.
Author_xml – sequence: 1
  givenname: Elise T.
  surname: Zeiser
  fullname: Zeiser, Elise T.
  organization: Research Service, VA Northeast Healthcare System, Cleveland, Ohio, USA
– sequence: 2
  givenname: Scott A.
  surname: Becka
  fullname: Becka, Scott A.
  organization: Research Service, VA Northeast Healthcare System, Cleveland, Ohio, USA
– sequence: 3
  givenname: John J.
  orcidid: 0000-0003-4033-7794
  surname: LiPuma
  fullname: LiPuma, John J.
  organization: Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan, USA
– sequence: 4
  givenname: Krisztina M.
  orcidid: 0000-0002-9976-7898
  surname: Papp-Wallace
  fullname: Papp-Wallace, Krisztina M.
  organization: Research Service, VA Northeast Healthcare System, Cleveland, Ohio, USA, Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA, Department of Biochemistry, Case Western Reserve University, Cleveland, Ohio, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36507667$$D View this record in MEDLINE/PubMed
BookMark eNptkF1LwzAUhoNM3IfeeS29VLAzH02a3AhzzA8YeOEE70Kapq6zbWrSTvbvrW4OBa8Oh_Pw8p5nCHqVrQwApwiOEcL8Sik9hohQHGJ8AAYICh4yKlgPDCBkLIw4jPpg6P0KdjsV8Aj0CaMwZiweADjRTb7Om01gs2C2eIERw0FjP5RLgydbmuCmdW9LW6TG5SrwdX0MDjNVeHOymyPwfDtbTO_D-ePdw3QyDxWJaROyVEFDjNEEx1yrCGmCKM4ITTKaJYJTErOUJiQjGHIlNKOIYaUMEylChgsyAtfb3LpNSpNqUzVOFbJ2eancRlqVy7-XKl_KV7uWgseYct4FnO8CnH1vjW9kmXttikJVxrZe4pgSxjgkcYdebFHlSyxXtnVV95pEUH4Zlp1h-W1YYtyxZ7977Qv9KO2Ayy2gnfXemWyP_Jv3CRHqhW8
Cites_doi 10.1128/JCM.00181-19
10.1038/s41586-021-03899-0
10.1021/acsinfecdis.7b00020
10.1128/AAC.00954-06
10.1128/AAC.41.11.2399
10.1128/AAC.01930-20
10.1128/AAC.38.2.407
10.1128/AAC.05769-11
10.1128/AEM.71.7.3917-3927.2005
10.1128/AAC.01140-18
10.1128/AAC.02315-18
10.1016/j.diagmicrobio.2018.06.005
10.1128/JCM.38.9.3165-3173.2000
ContentType Journal Article
Copyright Copyright © 2022 American Society for Microbiology.
Copyright © 2022 American Society for Microbiology. 2022 American Society for Microbiology
Copyright_xml – notice: Copyright © 2022 American Society for Microbiology.
– notice: Copyright © 2022 American Society for Microbiology. 2022 American Society for Microbiology
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1128/aac.01352-22
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
Pharmacy, Therapeutics, & Pharmacology
EISSN 1098-6596
ExternalDocumentID PMC9872588
01352-22
36507667
10_1128_aac_01352_22
Genre Research Support, U.S. Gov't, Non-P.H.S
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Cystic Fibrosis Foundation (CFF)
  grantid: N/A
  funderid: https://doi.org/10.13039/100000897
– fundername: Entasis Therapeutics (Entasis Therapeutics Inc.)
  grantid: N/A
  funderid: https://doi.org/10.13039/100017639
– fundername: United States Department of Veterans Affairs
  grantid: BX002872
  funderid: https://doi.org/10.13039/100000738
– fundername: ;
  grantid: N/A
– fundername: ;
  grantid: BX002872
GroupedDBID ---
.55
0R~
23M
2WC
39C
4.4
53G
5GY
5RE
5VS
6J9
AAGFI
AAYXX
ACGFO
ADBBV
AENEX
AGVNZ
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
CITATION
CS3
DIK
E3Z
EBS
F5P
FRP
GX1
H13
HH5
HYE
HZ~
H~9
K-O
KQ8
L7B
LSO
O9-
OK1
P2P
RHI
RNS
RPM
RSF
TR2
UHB
W2D
W8F
WH7
WOQ
X7M
CGR
CUY
CVF
ECM
EIF
NPM
RHF
8W4
AAPBV
ABFLS
ZA5
7X8
5PM
ID FETCH-LOGICAL-a375t-6da0e3eec3278ca41c3152f35bf5fb985376d5b3f3208a9c65162aae69d11e893
ISSN 0066-4804
1098-6596
IngestDate Thu Aug 21 18:37:43 EDT 2025
Thu Jul 10 20:20:49 EDT 2025
Tue Jan 24 20:26:45 EST 2023
Thu Jan 02 22:53:55 EST 2025
Tue Jul 01 04:13:31 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords ETX0462
beta-lactamase
Burkholderia
penicillin binding protein
beta-lactam
diazabicyclooctane
Language English
License All Rights Reserved. https://doi.org/10.1128/ASMCopyrightv2
All Rights Reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-a375t-6da0e3eec3278ca41c3152f35bf5fb985376d5b3f3208a9c65162aae69d11e893
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
The authors declare a conflict of interest. Entasis Therapeutics provided funding as a research grant to K.M.P.-W. to conduct this study.
ORCID 0000-0003-4033-7794
0000-0002-9976-7898
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/9872588
PMID 36507667
PQID 2753668037
PQPubID 23479
PageCount 3
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_9872588
proquest_miscellaneous_2753668037
asm2_journals_10_1128_aac_01352_22
pubmed_primary_36507667
crossref_primary_10_1128_aac_01352_22
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-01-24
PublicationDateYYYYMMDD 2023-01-24
PublicationDate_xml – month: 01
  year: 2023
  text: 2023-01-24
  day: 24
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: 1752 N St., N.W., Washington, DC
PublicationTitle Antimicrobial agents and chemotherapy
PublicationTitleAbbrev Antimicrob Agents Chemother
PublicationTitleAlternate Antimicrob Agents Chemother
PublicationYear 2023
Publisher American Society for Microbiology
Publisher_xml – name: American Society for Microbiology
References e_1_3_2_9_2
e_1_3_2_15_2
e_1_3_2_8_2
e_1_3_2_16_2
e_1_3_2_7_2
e_1_3_2_6_2
e_1_3_2_10_2
e_1_3_2_5_2
e_1_3_2_11_2
CLSI (e_1_3_2_2_2) 2022
e_1_3_2_4_2
e_1_3_2_12_2
e_1_3_2_13_2
e_1_3_2_14_2
Pandey N (e_1_3_2_3_2) 2022
References_xml – volume-title: Performance standards for antimicrobial susceptibility testing
  year: 2022
  ident: e_1_3_2_2_2
– ident: e_1_3_2_11_2
  doi: 10.1128/JCM.00181-19
– ident: e_1_3_2_13_2
  doi: 10.1038/s41586-021-03899-0
– volume-title: Beta lactam antibiotics.
  year: 2022
  ident: e_1_3_2_3_2
– ident: e_1_3_2_4_2
  doi: 10.1021/acsinfecdis.7b00020
– ident: e_1_3_2_5_2
  doi: 10.1128/AAC.00954-06
– ident: e_1_3_2_8_2
  doi: 10.1128/AAC.41.11.2399
– ident: e_1_3_2_10_2
  doi: 10.1128/AAC.01930-20
– ident: e_1_3_2_9_2
  doi: 10.1128/AAC.38.2.407
– ident: e_1_3_2_16_2
  doi: 10.1128/AAC.05769-11
– ident: e_1_3_2_15_2
  doi: 10.1128/AEM.71.7.3917-3927.2005
– ident: e_1_3_2_6_2
  doi: 10.1128/AAC.01140-18
– ident: e_1_3_2_12_2
  doi: 10.1128/AAC.02315-18
– ident: e_1_3_2_7_2
  doi: 10.1016/j.diagmicrobio.2018.06.005
– ident: e_1_3_2_14_2
  doi: 10.1128/JCM.38.9.3165-3173.2000
SSID ssj0006590
Score 2.4092557
Snippet Burkholderia cepacia complex (Bcc) and Burkholderia gladioli are opportunistic human pathogens that are inherently multidrug resistant, limiting treatment...
Burkholderia cepacia complex (Bcc) and Burkholderia gladioli are opportunistic human pathogens that are inherently multidrug resistant, limiting treatment...
SourceID pubmedcentral
proquest
asm2
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage e0135222
SubjectTerms Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Antimicrobial Chemotherapy
Burkholderia
Burkholderia cepacia complex
Burkholderia Infections - drug therapy
Ceftazidime - therapeutic use
Humans
Susceptibility
Trimethoprim, Sulfamethoxazole Drug Combination - pharmacology
Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use
Title Activity of ETX0462 toward Some Burkholderia spp
URI https://www.ncbi.nlm.nih.gov/pubmed/36507667
https://journals.asm.org/doi/10.1128/aac.01352-22
https://www.proquest.com/docview/2753668037
https://pubmed.ncbi.nlm.nih.gov/PMC9872588
Volume 67
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELbKENNeEBQY5ZcCgr10KY1dO85jmUDTRFGldVLFS-Q4DoumpNGSPnRv_OecYydNGUiwl6iKU8fyfb7c2ffdIfSe0ESwgFIXwBG5EykSN8CRhOXOFFaaNFIThWff2OnF5GxJl73ezy67pIpG8uaPvJK7SBXugVw1S_Y_JNt2CjfgN8gXriBhuP6TjKfS1n7Q4YGLpWaAgi2p42CH56tMDT-tr6_08ZIey7Asiq4lOs2rNEvrNEw6XcCPmulWk9wuVWZpWe12-3elSzbbMLBSDRej1o1X8qq2P8_rJA_TtuFrOl9noon2HZ61DXNRFG5n_16rmZsqzcVwNuruQWAdgeXi7R5ke7jUjTSdpdtMUl0NzBjgwpQcHimjdHVOU0ZNZdtGK5siHV303Vb2WBMYBOAO7FiKXUNw7si9yGrBE7BCfWY73E2uPZ-dBNzHlPN76D4GTwM3Gz72Yw7DMiwmO-yGO4H5x-6LD9B-8xb4tosyw7t2zi3n5fcY3I5Rs3iEHlpvxJkaaD1GPZX30QNTn3TTR_szG3nRR0dzk-N8c-wstpS98tg5cubb7OebJ2jcgNJZJY4FpWNA6WhQOl1QOgDKp-jiy-fFyalry3K4gvi0clksxoooJQn2uRQTTxIwAhNCo4QmUcB1gqCYRiQheMxFIBn1GBZCsSD2PAX28TO0l69y9Rw5NGIR8SQlcQKeg8dE7I9jLqAjySMZ8AF6p-cytGuuDGuXFfMQ5j6s5z7EeIA-NDMdFiZFy1-ee9uIIQQdqg_GRK5W6zLE4LMzxsfEH6BDI5a2p0asA-TvCKx9QOdn323J08s6T7tF1os7__MlOtiutldor7peq9dgA1fRmxqlvwBLY6-5
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Activity+of+ETX0462+toward+Some+Burkholderia+spp&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=Zeiser%2C+Elise+T.&rft.au=Becka%2C+Scott+A.&rft.au=LiPuma%2C+John+J.&rft.au=Papp-Wallace%2C+Krisztina+M.&rft.date=2023-01-24&rft.pub=American+Society+for+Microbiology&rft.issn=0066-4804&rft.eissn=1098-6596&rft.volume=67&rft.issue=1&rft_id=info:doi/10.1128%2Faac.01352-22&rft_id=info%3Apmid%2F36507667&rft.externalDocID=PMC9872588
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0066-4804&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0066-4804&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0066-4804&client=summon